Progress in Alzheimer’s and Parkinson’s Diseases

Cytokines in Parkinson’s disease

2000 • 300 citations

Mitochondrial Dysfunction and Alzheimers Disease

2006 • 70 citations

Interval Hypoxic Training Prevents Oxidative Stress in Striatum and Locomotor Disturbances in a Rat Model of Parkinsonism

1998 • 9 citations

S 17092-1, A New Post-Proline Cleaving Enzyme Inhibitor: Memory Enhancing Effects and Substance P Neuromodulatory Activity

1998 • 8 citations

N-Methyl(R)Salsolinol and (R)SalsolinolN-Methyltransferase as Possible Pathogenic Factors in Parkinson’s Disease

1998 • 6 citations

N-Methyl(R)Salsolinol: A Neurotoxin Candidate to Induce Parkinson’s Disease Causes Apoptosis in Dopamine Cells

1998 • 5 citations

Age-Related Na,K-Atpase mRNA Expression and Alzheimer’s Disease

1998 • 5 citations

Antisense Oligodeoxynucleotide Dependent Suppression of Acetylcholinesterase Expression Reduces Process Extension from Primary Mammalian Neurons

1998 • 4 citations

Pathophysiology of Hereditary Progressive Dystonia with Marked Diurnal Fluctuation-its Characteristics in Contrast to other Dopa-Responsive Disorders

1998 • 3 citations

Intracerebroventricular Administration of Beta-Amyloid Peptide (25-35) Induces Oxidative Stress and Neurodegeneration in Rat Brain

1998 • 3 citations

Identification of Peptides Binding to Presenilin 1 by Screening of Random Peptide Display Libraries

1998 • 3 citations

Crystallographic Studies on Complexes of Acetylcholinesterase with the Natural Cholinesterase Inhibitors Fasciculin and Huperzine A

1998 • 2 citations

Neuronal Oxidative Stress is a Common Feature of Alzheimer’s and Parkinson’s Diseases

1998 • 2 citations

Centromeric Disturbances Affecting All Chromosomes of Cultured Lymphocytes Obtained From Alzheimer’s Disease Patients

1998 • 2 citations

Comparative Study of Antioxidants’ Action on Membrane-Bound Acetylcholinesterase (AChE) of Blood Erythrocytes and Brain Synaptosomes

1998 • 2 citations

Indices of Oxidative Stress in the Peripheral Blood of De Novo Patients With Parkinson’s Disease

1998 • 2 citations

Anthracyclines and Amyloidosis

1998 • 2 citations

Insulin, Insulin Receptors, and Igf-I Receptors in Post-Mortem Human Brain in Alzheimer’s Disease

1998 • 2 citations

Lipid Composition of Different Brain Regions in Patients with Alzheimer’s Disease and Multi-Infarct Dementia

1998 • 2 citations

Ultra-Low Doses of Antioxidant and Acetylcholine Modify the Lipid Phase and Kinetic Properties of Acetylcholinesterase in Murine Brain Membranes

1998 • 1 citations

Direct Evidence that Lactate is an Obligatory Aerobic Energy Substrate for Functional Recovery Posthypoxia in Vitro

1998 • 1 citations

Neuropsychological and Positron Emission Tomographic Comparisons of Alzheimer’s, Multi-Infarct, and Parkinson’s Disease Dementias

1998 • 1 citations

Acylphosphatase Levels In Alzheimer’s Disease Cultured Skin Fibroblasts

1998 • 1 citations

Cognitive and Non-Cognitive Symptoms in Senile Dementia

1998 • 1 citations

Verbal and Motor Memory in Alzheimer’s Disease: Release from Proactive Inhibition

1998 • 1 citations

Quaternary-Lipophilic Carbamates with Blood Brain Barrier Permeability as Potential Drugs for Memory Impairment Associated with Cholinergic Deficiency

1998 • 1 citations

Common Mechanisms in Cell Cycle and Cell Death

1998 • 1 citations

HB-GAM, a Novel Amyloid Associated Protein, is Present in Prion Related Disorders and other Cerebral Amyloidoses

1998 • 1 citations

APOE Genotype-Related Blood Pressure in Senile Dementia

1998 • 1 citations

Harmonization of Drug Approval Guidelines in Alzheimer’s and Parkinson’s Diseases

1998 • 1 citations

Effects of Progressive Neurological Disease on Interpersonal Relations Between Patients and Family Members

1998 • 1 citations

S 12024-2, A Cognitive Enhancer, Interacts with Nicotinic Neurotransmission

1998 • 1 citations

Tacrine Reduces the Secretion of Soluble Amyloid Beta-Peptides in a Neuroblastoma Cell Line

1998 • 1 citations

What can be Learned from the use of HuAChE Mutants for Evaluation of Potential Alzheimer’s Drugs

1998 • 1 citations

How Can we Improve the Drug Development Process in Alzheimer’s Disease?

1998 • 1 citations

Divergent Metabolism of Apolipoproteins E3 and E4 by Cells

1998 • 1 citations

Molecular Cloning, Transient Expression, and Neurotrophic Effect for DA Neurons of Human Brain Derived Neurotrophic Factor

1998 • 1 citations

Cognitive Deficits in Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Chorea

1998 • 1 citations

Lewy Body Influence on Tacrine Efficacy

1998 • 1 citations

Tacrine Treatment in Parkinson’s Disease Dementia

1998 • 1 citations

Effect of AF64A/NGF Treatment on ChAT MRNA Expression in the Septo-Hippocampal Pathway and Striatum

1998 • 1 citations

a Chromosome 6q-Linked Parkinsonism

1998 • 1 citations

Differential Susceptibility of Human Apolipoprotein E Isoforms to Oxidation and Consequences on their Interaction with Phospholipids

1998 • 1 citations

Dementia Associated Sleep Disorders

1998 • 1 citations

Trial to Prevent Neurodegeneration in Persons Genetically Predisposed to Alzheimer’s Disease

1998 • 1 citations

THE MOLECULAR BASIS UNDERLYING THE DISCRETE ACTIVATION OF SIGNAL TRANSDUCTION PATHWAYS BY SELECTIVE MUSCARINIC AGONISTS Relevance to Treatment of Alzheimer's Disease

1998 • 1 citations

Regulation of APP Metabolism by Protein Phosphorylation

1998 • 1 citations

The Non-Catalytic Role and Complex Management of Acetylcholinesterase in the Mammalian Brain Call for RNA-Based Therapies

1998 • 1 citations

Dopaminergic Responsiveness of Hypokinesia but not of Rigidity and Tremor is Reduced in Fluctuating Parkinson’s Disease

1998 • 1 citations